Glycolysis-related gene expression profiling serves as a novel prognosis risk predictor for human hepatocellular carcinoma
L Zhang, Y Li, Y Dai, D Wang, X Wang, Y Cao, W Liu… - Scientific Reports, 2021 - nature.com
Metabolic pattern reconstruction is an important factor in tumor progression. Metabolism of
tumor cells is characterized by abnormal increase in anaerobic glycolysis, regardless of high …
tumor cells is characterized by abnormal increase in anaerobic glycolysis, regardless of high …
Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells
R Sommaggio, E Cappuzzello, A Dalla Pietà… - …, 2020 - Taylor & Francis
ABSTRACT Cytokine-Induced Killer (CIK) cells share several functional and phenotypical
properties of both T and natural killer (NK) cells. They represent an attractive approach for …
properties of both T and natural killer (NK) cells. They represent an attractive approach for …
High expression of DEPDC1 promotes malignant phenotypes of breast cancer cells and predicts poor prognosis in patients with breast cancer
H Zhao, M Yu, L Sui, B Gong, B Zhou, J Chen… - Frontiers in …, 2019 - frontiersin.org
DEP domain containing 1 (DEPDC1) is a novel tumor-associated gene, which is aberrantly
expressed in multiple types of cancer and involves in tumorigenesis and cancer …
expressed in multiple types of cancer and involves in tumorigenesis and cancer …
Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines
A Dalla Pietà, D Carpanese, A Grigoletto… - Cellular & Molecular …, 2021 - nature.com
One of the main goals of vaccine research is the development of adjuvants that can enhance
immune responses and are both safe and biocompatible. We explored the application of the …
immune responses and are both safe and biocompatible. We explored the application of the …
DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway
W Guo, H Li, H Liu, X Ma, S Yang… - Oncology …, 2019 - spandidos-publications.com
Abstract DEP domain containing 1 (DEPDC1) functions as an oncogene in hepatocellular
carcinoma (HCC). However, the underlying mechanism of DEPDC1 remains largely …
carcinoma (HCC). However, the underlying mechanism of DEPDC1 remains largely …
Roles of DEPDC1 in various types of cancer
D Liu, H Li, J Ouyang - Oncology Letters, 2024 - spandidos-publications.com
Dishevelled, EGL-10 and pleckstrin domain-containing 1 (DEPDC1) has been identified as
a crucial factor in the development and progression of various types of cancer. This protein …
a crucial factor in the development and progression of various types of cancer. This protein …
[HTML][HTML] Characterization of antigen presentation capability for neoantigen-based products using targeted LC-MS/MS method
N Xiang, K Zhang, Y Zhao, C Xu, X Zhang… - Journal of Pharmaceutical …, 2024 - Elsevier
The generation of an immune response in neoantigen-based products relies on antigen
presentation, which is closely analyzed by bioassays for T-cell functions such as tetramer or …
presentation, which is closely analyzed by bioassays for T-cell functions such as tetramer or …
Structural immunoinformatics approach for rational design of a multi-epitope vaccine against triple negative breast cancer
TNBC is a highly malignant breast cancer known for its aggressive behavior affecting young
female adults. The standard treatment for TNBC includes surgery, chemotherapy, and …
female adults. The standard treatment for TNBC includes surgery, chemotherapy, and …
Targeting DEP domain containing 1 in anaplastic thyroid carcinoma: Implications for stemness regulation and malignant phenotype suppression
C Zhu, S Ke, Y Li, W Zhang, Y Che, R Zhang, P Huang… - Heliyon, 2024 - cell.com
Background Anaplastic thyroid carcinoma (ATC), a rare but highly aggressive endocrine
malignancy, is characterized by a significant presence of cancer stem-like cells (CSCs) …
malignancy, is characterized by a significant presence of cancer stem-like cells (CSCs) …
Antibody‐dependent cell‐mediated cytotoxicity using T cells with NK‐like phenotype in combination with avelumab, an anti‐PD‐L1 antibody
D Liu, Y Hu, J Wei, W Zhang, C Piao, Y Lu… - …, 2022 - Wiley Online Library
Though the PD‐L1 checkpoint inhibitor avelumab has shown efficacy in the treatment of
some types of cancer, improved treatment strategies are desperately needed. We evaluated …
some types of cancer, improved treatment strategies are desperately needed. We evaluated …